Expert Interview: The Art and Science of Intrathecal Pain Management
Expert InterviewPremiere Date: Tuesday, August 11, 2015
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, August 11, 2016
Note: Credit Is No Longer Available
|Gladstone C. McDowell II, MD
Integrated Pain Solutions
Intrathecal (IT) therapy has become an increasingly accepted alternative to standard medical management for patients with moderate-to-severe intractable pain. Appropriate patient and treatment selections are imperative to achieving optimum outcomes.1 However, even in the right patient, the right drug may not be efficacious or may result in intolerable adverse effects if the treatment is not initiated properly. Evidence suggests that ongoing education is warranted to build and strengthen the use of evidence-based, best practices among clinicians regarding use of IT therapy in pain management.2
This Expert Interview will help clinicians identify patients who are appropriate candidates for IT pain management, implement evidence-based trialing strategies, and then devise and implement an IT pain treatment plan that maximizes efficacy and minimizes side effects.
- Mitchell AA, Sapienza-Crawford AJ, Hanley KL, et al. Administering ziconotide and monitoring patients treated with ziconotide: expert opinion. Pain Manag Nurs. 2013;14(3):e84-e94. PMID: 23972874.
- Deer TR, Smith HS, Cousins M, et al. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician. 2010;13(3):E175-E213. PMID: 20495597.
This educational activity centers on the CME Outfitters Make One Change statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change statement for this activity is:
Learners will implement an evidence- and best practice-based approach to the initiation of intrathecal pain management in all appropriate patients.
At the end of this CE activity, participants should be able to:
- Utilize current, evidence-based, best-practice criteria to guide appropriate patient selection for intrathecal pain treatment.
- Implement best practice-based intrathecal medication trialing strategies as a routine component of an individualized treatment approach to pain management.
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Pain physicians and other clinicians whose scope of practice includes providing care to patients with intractable pain.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. McDowell has disclosed that he has received research and grant support from Jazz Pharmaceuticals, Inc. and Mallinckrodt Pharmaceuticals. He is on the speakers bureau of Jazz Pharmaceuticals, Inc. and Medtronic, Inc. He serves as a consultant for Jazz Pharmaceuticals, Inc. and Medtronic, Inc.
Tony Graham, MD (peer reviewer) has nothing to disclose.
Robert Kennedy (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).